The U.S. Cell Therapy Market Top Companies

The U.S. cell therapy market has witnessed exponential growth in recent years, driven by advancements in medical research and an increasing demand for innovative treatments. This article delves into the top companies leading the charge in the cell therapy sector, highlighting their contributions and unique offerings.

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a leading biopharmaceutical company with a strong presence in the cell therapy market through its subsidiary, Kite Pharma. Kite Pharma specializes in CAR-T therapies for hematologic cancers, with Yescarta (axicabtagene ciloleucel) being one of their flagship products. Gilead’s robust clinical pipeline and commitment to advancing cell therapy research underscore their role as a major player in the industry. Their strategic acquisitions and collaborations continue to drive innovation and expand their therapeutic offerings.

Company Name Gilead Sciences Inc.
Headquarters California, U.S.
Pipeline List of cell therapies under development:

  • CD19 CAR (KITE-197), Relapsed/refractory diffuse large B-cell lymphoma (Phase 1)
  • CD19/CD20 bicistronic (KITE-753), Relapsed/refractory diffuse large B-cell lymphoma (Phase 1)
  • CD19/CD20 bicistronic (KITE-363), Relapsed/refractory diffuse large B-cell lymphoma (Phase 1)
  • Anitocabtagene autoleucel (iMMagine-1), Relapsed/refractory multiple myeloma (Phase 2)
  • Brexucabtagene autoleucel (ZUMA-4), Pediatric acute lymphocytic leukemia/ non-Hodgkin lymphoma (Phase 2)
  • Axicabtagene ciloleucel (ZUMA-24), 2L large B-cell lymphoma outpatient (Phase 2)
  • Axicabtagene ciloleucel (ZUMA-23), 1L high-risk large B-cell lymphoma (Phase 3)
  • Axicabtagene ciloleucel (ZUMA-22), 2L+ high-risk follicular lymphoma (Phase 3)

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is focused on developing allogeneic T-cell therapies for cancer and autoimmune diseases. Their Epstein-Barr virus (EBV)-specific T-cell platform has shown significant promise in treating EBV-associated cancers and multiple sclerosis. Atara’s off-the-shelf T-cell therapies offer a unique advantage by eliminating the need for personalized cell collection and processing. With a strong emphasis on innovation and patient-centric solutions, Atara Biotherapeutics is poised to make a substantial impact on the cell therapy market.

Company Name Atara Biotherapeutics Inc.
Headquarters California, U.S.
Pipeline In order to set the path for future therapies, the firm is making a lot of effort to address important unmet needs in autoimmune disorders and cancer. Numerous cell treatments are being researched.

  • Tab-celĀ® is in the early stages of research and is being studied for individuals with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD). Targeting and eradicating EBV-infected cells is the goal of Tab-cel, an allogeneic T-cell immunotherapy.
  • The EBV T-cell platform is used in the clinical development of ATA3219, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell treatment with a memory phenotype, unedited T-cell receptor, and next-generation 1XX co-stimulatory domain.
  • Aiming for an IND application in H2 2025, the off-the-shelf, allogeneic CD19/CD20 CAR T program is ATA3431.
  • EBV-infected B cells and plasma cells, which are thought to be the etiology of MS, are the focus of the experimental allogeneic T-cell immunotherapy known as ATA188.

Download a sample of this report @

Aurion Biotech

Aurion Biotech is at the forefront of cell therapy innovation, focusing on novel treatments for eye diseases. Their flagship product, a cell-based therapy for corneal endothelial disease, has shown promising results in clinical trials. Aurion Biotech’s approach involves the regeneration of corneal endothelial cells, potentially reducing the need for corneal transplants. Their groundbreaking research and development efforts aim to restore vision and improve the quality of life for millions of patients globally.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is renowned for its pioneering work in the treatment of cystic fibrosis. Leveraging their expertise in genetic therapies, Vertex has expanded into the cell therapy market. Their acquisition of Semma Therapeutics has bolstered their capabilities in stem cell-derived therapies for type 1 diabetes. Vertex’s innovative approaches and strong pipeline position them as a key player in the U.S. cell therapy market, with a focus on developing transformative treatments for serious diseases.

Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. (CBMG) is a leading biopharmaceutical company specializing in immunotherapies for cancer and stem cell therapies for degenerative diseases. CBMG’s portfolio includes CAR-T therapies targeting various forms of cancer, including non-Hodgkin lymphoma and multiple myeloma. Their commitment to advancing cell therapy technologies and their extensive clinical trial network make CBMG a prominent figure in the industry, driving forward the development of cutting-edge treatments.

Nkarta, Inc.

Nkarta, Inc. is a biotechnology company dedicated to the development of engineered natural killer (NK) cell therapies. Their proprietary technology enhances the efficacy and persistence of NK cells, offering a promising approach to cancer treatment. Nkarta’s lead product candidates, NKX101 and NKX019, are designed to target specific cancer cells with high precision. The company’s innovative strategies and robust clinical pipeline underscore their potential to revolutionize the cell therapy landscape.

Johnson & Johnson

Johnson & Johnson, a global healthcare leader, has made significant strides in the cell therapy arena through its subsidiary, Janssen Pharmaceuticals. Their focus includes CAR-T therapies for hematologic malignancies and regenerative medicine for musculoskeletal disorders. Johnson & Johnson’s extensive resources, coupled with their commitment to research and development, enable them to advance groundbreaking cell therapies. Their comprehensive approach aims to address unmet medical needs and enhance patient outcomes.

CARGO Therapeutics, Inc.

CARGO Therapeutics, Inc. is a trailblazer in the field of gene and cell therapies. Their proprietary platform, CRISPR/Cas9-based gene editing, allows for precise modifications at the cellular level, opening new avenues for the treatment of genetic disorders and cancers. CARGO’s pipeline includes therapies for sickle cell disease and beta-thalassemia, among others. Their cutting-edge technology and strategic collaborations position them as a key player in the U.S. cell therapy market.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. BMS’s acquisition of Celgene has significantly enhanced their cell therapy portfolio, particularly in the area of CAR-T therapies. Their products, such as Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), have received FDA approval for the treatment of certain hematologic cancers. BMS’s commitment to advancing cell therapy research continues to drive progress in this rapidly evolving field.

Selecta Bioscience

Selecta Bioscience is pioneering the development of immune tolerance therapies using their ImmTOR platform. This technology aims to mitigate unwanted immune responses, enhancing the efficacy and safety of gene and cell therapies. Selecta’s approach holds promise for treating rare genetic disorders and enabling repeated dosing of biologic therapies. Their innovative strategies and focus on immune modulation make Selecta Bioscience a significant contributor to the cell therapy market.

In conclusion, the U.S. cell therapy market is marked by significant advancements and contributions from top companies like Aurion Biotech, Vertex Pharmaceuticals, Cellular Biomedicine Group, Nkarta, Atara Biotherapeutics, Johnson & Johnson, CARGO Therapeutics, Bristol-Myers Squibb, Selecta Bioscience, and Gilead Sciences. These companies are at the cutting edge of medical innovation, developing transformative therapies that have the potential to revolutionize the treatment of various diseases.

To own our research study instantly, Click here @

Read more about U.S. Cell Therapy Market:

You can place an order or ask any questions, please feel free to contact us at

About Us

Healthcare Web Wire is a premier subsidiary of Towards Healthcare, dedicated to providing comprehensive insights and information related to the healthcare industry. With a commitment to delivering accurate and timely updates, Healthcare Web Wire serves as a vital resource for professionals, enthusiasts, and stakeholders within the healthcare sector. Our platform serves as a central hub for the latest news, trends and developments shaping the healthcare landscape. Join us on Healthcare Web Wire and become part of a vibrant community dedicated to advancing healthcare knowledge and shaping the future of healthcare worldwide.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us:

By Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.